Neuropeptides in the pathophysiology and treatment of cachexia

Current Opinion in Supportive and Palliative Care

Volumn 4, Issue 4, 2010, Pages 266-271

  Krasnow, Stephanie M ^a   Marks, Daniel L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cachexia; Cytokines; Ghrelin; Inflammation; Melanocortin

Indexed keywords

NEUROPEPTIDE;

ANIMAL; ARTICLE; CACHEXIA; HUMAN; METABOLISM;

ANIMALS; CACHEXIA; HUMANS; NEUROPEPTIDES;

EID: 78449243097     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32833e48e7     Document Type: Article

References (70)

1. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol 2010; 26:146-151.
2. Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol 2010; 25:711-724.
3. Freeman LM. The pathophysiology of cardiac cachexia. Curr Opin Support Palliat Care 2009; 3:276-281.
4. Faintuch J, Soeters PB, Osmo HG. Nutritional and metabolic abnormalities in pre-AIDS HIV infection. Nutrition 2006; 22:683-690.
5. Evans WJ, Morley JE, Argiles J, et al. Cachexia: A new definition. Clin Nutr 2008; 27:793-799.
6. Evans WK, Makuch R, Clamon GH, et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res 1985; 45:3347-3353.
7. Morley JE, Thomas DR, Wilson MM. Cachexia: Pathophysiology and clinical relevance. Am J Clin Nutr 2006; 83:735-743.
8. Mak RH, Cheung W, Cone RD, Marks DL. Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia. Nat Clin Pract Nephrol 2006; 2:527-534.
9. Ren SG, Seliktar J, Li X, et al. Measurement of leukemia inhibitory factor in biological fluids by radioimmunoassay. J Clin Endocrinol Metab 1998; 83:1275-1283.
10. Grunfeld C, Feingold KR. Regulation of lipid metabolism by cytokines during host defense. Nutrition 1996; 12:S24-S26.
11. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 2007; 13:1356-1361.
12. Layé S, Parnet P, Goujon E, Dantzer R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res Mol Brain Res 1994; 27:157-162.
13. Grossberg AJ, Scarlett JM, Marks DL. Hypothalamic mechanisms in cachexia. Physiol Behav 2010; 100:478-489. A comprehensive review on hypothalamic neuropeptides that mediate illnessinduced anorexia and lesser studied aspects of cachexia, including lethargy, insulin resistance and reproductive dysfunction.
14. Laflamme N, Rivest S. Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain. J Neurochem 1999; 73:309-321.
15. Elmquist JK, Scammell TE, Jacobson CD, Saper CB. Distribution of Fos-like immunoreactivity in the rat brain following intravenous lipopolysaccharide administration. J Comp Neurol 1996; 371:85-103.
16. Wisse BE, Ogimoto K, Tang J, et al. Evidence that lipopolysaccharideinduced anorexia depends upon central, rather than peripheral, inflammatory signals. Endocrinology 2007; 148:5230-5237.
17. Plata-Salamán CR. Anorexia induced by activators of the signal transducer gp 130. Neuroreport 1996; 7:841-844.
18. Sonti G, Ilyin SE, Plata-Salamán CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996; 270:R1394-R1402.
19. Wallenius K, Wallenius V, Sunter D, et al. Intracerebroventricular interleukin-6 treatment decreases body fat in rats. Biochem Biophys Res Commun 2002; 293:560-565.
20. DeBoer MD, Scarlett JM, Levasseur PR, et al. Administration of IL-1β to the 4th ventricle causes anorexia that is blocked by agouti-related peptide and that coincides with activation of tyrosine-hydroxylase neurons in the nucleus of the solitary tract. Peptides 2009; 30:210-218.
21. Arruda AP, Milanski M, Romanatto T, et al. Hypothalamic actions of tumor necrosis factor alpha provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology 2010; 151:683-694. This paper demonstrates an essential role for central TNF-a signaling in two rodent models of cachexia.
22. Tao YX. The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology. Endocr Rev 2010. [Epub ahead of print]
23. Ollmann MM, Wilson BD, Yang YK, et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997; 278:135-138.
24. Scarlett JM, Jobst EE, Enriori PJ, et al. Regulation of central melanocortin signaling by interleukin-1 beta. Endocrinology 2007; 148:4217-4225.
25. Scarlett JM, Zhu X, Enriori PJ, et al. Regulation of agouti-related protein messenger ribonucleic acid transcription and peptide secretion by acute and chronic inflammation. Endocrinology 2008; 149:4837-4845.
26. Macia L, Viltart O, Delacre M, et al. Interleukin-7, a new cytokine targeting the mouse hypothalamic arcuate nucleus: Role in body weight and food intake regulation. PLoS One 2010; 5:e9953. This paper reveals a novel role for interleukin-7 in the central control of feeding and body weight regulation, possibly via its actions on hypothalamic POMC and AgRP neurons.
27. Grossberg AJ, Scarlett JM, Zhu X, et al. Arcuate nucleus proopiomelanocortin neurons mediate the acute anorectic actions of leukemia inhibitory factor via gp130. Endocrinology 2010; 151:606-616. This series of experiments demonstrated that POMC neurons are direct targets for central LIF signaling, and that gp130 signaling in POMC neurons is essential for acute LIF-induced anorexia in mice.
28. Jang PG, Namkoong C, Kang GM, et al. NF-kappaB activation in hypothalamic pro-opiomelanocortin neurons is essential in illness- and leptin-induced anorexia. J Biol Chem 2010; 285:9706-9715. This study is among the first to investigate the intracellular signaling mechanisms by which inflammatory mediators activate POMC neurons in the setting of acute illness/inflammation. Notably, mice with impaired NF-kB function in POMC neurons resist developing anorexia in response to acute inflammatory challenges.
29. Cheung W, Yu PX, Little BM, et al. Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 2005; 115:1659-1665.
30. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001; 61:1432-1438.
31. Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142:3292-3301.
32. Scarlett JM, Bowe DD, Zhu X, et al. Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure. J Endocrinol 2010; 206:121-130. These experiments revealed the beneficial effects of melanocortin receptor blockade on feeding, weight gain and lean body mass accumulation in two experimental models of cardiac cachexia.
33. Lietz K, John R, Burke EA, et al. Pretransplant cachexia and morbid obesity are predictors of increased mortality after heart transplantation. Transplantation 2001; 72:277-283.
34. DeBoer MD. Update on melanocortin interventions for cachexia: Progress toward clinical application. Nutrition 2010; 26:146-151.
35. Chen C, Tucci FC, Jiang W, et al. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists. Bioorg Med Chem 2008; 16:5606-5618.
36. Weyermann P, Dallmann R, Magyar J, et al. Orally available selective melanocortin- 4 receptor antagonists stimulate food intake and reduce cancerinduced cachexia in mice. PLoS One 2009; 4:e4774. One of the first published preclinical studies investigating the efficacy of orally available melanocortin receptor antagonists. Both compounds attenuated the loss of lean and fat mass in tumor-bearing mice.
37. Peter JC, Lecourt AC, Weckering M, et al. A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: Effectiveness after peripheral and central administration. J Pharmacol Exp Ther 2010; 333:478-490. Results from these experiments in healthy rats support the idea that monoclonal antibody therapy may be a viable anti-cachexia therapy.
38. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of AgRP and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1:271-272.
39. Chee MJ, Colmers WF. Y eat? Nutrition 2008; 24:869-877.
40. Stofkova A, Haluzik M, Zelezna B, et al. Enhanced expressions of mRNA for neuropeptide Y and interleukin 1 beta in hypothalamic arcuate nuclei during adjuvant arthritis-induced anorexia in Lewis rats. Neuroimmunomodulation 2009; 16:377-384.
41. Chance WT, Balasubramaniam A, Thompson H, et al. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996; 17:797-801.
42. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
43. Castaneda TR, Tong J, Datta R, et al. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol 2010; 31:44-60.
44. Akamizu T, Takaya K, Irako T, et al. Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 2004; 150:447-455.
45. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407:908-913.
46. Willesen MG, Kristensen P, Rømer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999; 70:306-316.
47. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145:2607-2612.
48. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activationinduced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114:57-66.
49. Legakis I, Stathopoulos J, Matzouridis T, Stathopoulos GP. Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals. Anticancer Res 2009; 29:3949-3952.
50. Takahashi M, Terashima M, Takagane A, et al. Ghrelin and leptin levels in cachectic patients with cancer of the digestive organs. Int J Clin Oncol 2009; 14:315-320.
51. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: Relationships between ghrelin and anabolic/catabolic factors. Circulation 2001; 104:2034-2038.
52. Yoshimoto A, Mori K, Sugawara A, et al. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 2002; 13:2748-2752.
53. Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:879-882.
54. Hataya Y, Akamizu T, Hosoda H, et al. Alterations of plasma ghrelin levels in rats with lipopolysaccharide-induced wasting syndrome and effects of ghrelin treatment on the syndrome. Endocrinology 2003; 144:5365-5371.
55. Deboer MD, Zhu X, Levasseur PR, et al. Ghrelin treatment of chronic kidney disease: Improvements in lean body mass and cytokine profile. Endocrinology 2008; 149:827-835.
56. DeBoer MD, Zhu XX, Levasseur P, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007; 148:3004-3012.
57. Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104:1430-1435.
58. Akashi YJ, Palus S, Datta R, et al. No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol 2009; 137:267-275. These experiments demonstrated that chronic ghrelin treatment improves lean body mass retention in a rat model of chronic heart failure, in the absence of any significant improvements in cardiac function.
59. Barazzoni R, Zhu X,Deboer M, et al.Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int 2010; 77:23-28. Exogenous ghrelin treatment improves metabolic function in the skeletal muscle of nephrectomized rats, at least in part via mechanisms that operate independently of ghrelin-induced food intake.
60. Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 2010; 91:1143S-1147S.
61. Garcia JM, Polvino WJ. Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: Results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 2007; 12:594-600.
62. Garcia JM, Graham C, Kumor K, Polvino W. A Phase II, randomized, placebocontrolled, double blind study of the efficacy and safety of RC-1291 for the treatment of cancer-cachexia. J Clin Oncol 2007; 25:9133 [abstract].
63. Haynes AC, Jackson B, Overend P, et al. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 1999; 20:1099-1105.
64. Yamanaka A, Sakurai T, Katsumoto T, et al. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 1999; 849:248-252.
65. Shiuchi T, Haque MS, Okamoto S, et al. Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab 2009; 10:466-480. This paper reveals a role for hypothalamic orexin neurons in skeletal muscle glucose metabolism.
66. Anaclet C, Parmentier R, Ouk K, et al. Orexin/hypocretin and histamine: Distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci 2009; 29:14423-14438.
67. Gaykema RP, Goehler LE. Lipopolysaccharide challenge-induced suppression of Fos in hypothalamic orexin neurons: Their potential role in sickness behavior. Brain Behav Immun 2009; 23:926-930. These experiments hint at a potential role of reduced activity of hypothalamic orexin neurons in illness-induced lethargy.
68. Hollis JH, Lemus M, Evetts MJ, Oldfield BJ. Central interleukin-10 attenuates lipopolysaccharide-induced changes in food intake, energy expenditure and hypothalamic Fos expression. Neuropharmacology 2010; 58:730-738.
69. Blackhall L, Petroni G, Shu J, et al.Apilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med 2009; 12:433-439. This small study in humansubjectsdemonstrated thatmodafinil (aCNSstimulant that increases orexin activity) reduces fatigue and improves quality of life in cancer patients.
70. Spathis A, Dhillan R, Booden D, et al. Modafinil for the treatment of fatigue in lung cancer: A pilot study. Palliat Med 2009; 23:325-331. Another pilot study that tested the safety and efficacy of modafinil in cancer patients. Modafinil lessened fatigue, perhaps by virtue of its ability to stimulate hypothalamic orexin neuronal activity.